Employing Lymphoid Resident Commensal Bacteria to Modulate Chronic Inflammatory Diseases

Background & Unmet Need

• The mammalian GI tract is colonized by a vibrant community of microorganisms, with roles in nutrient metabolism, resisting infection, and immune system development
• Translocation of commensal bacteria can lead to pro-inflammatory immune response and disease pathogenesis (e.g., IBD, metabolic disorders)
• Unmet Need: Improved understanding of translocation of commensal bacteria and strategies for modulating the host microbiome to treat chronic inflammatory diseases

Technology Overview

• The Technology: Lymphoid-tissue-resident commensal bacteria (LRCs) as key regulators of the pro-inflammatory response and potential biotherapeutic agents to treat chronic inflammatory disease
• LRCs colonize and persist within murine dendritic cells (DCs) and modulate cytokine production to curb inflammation
• The induced cytokines protected mice from lethal intestinal damage

Technology Applications

• Treatment and prevention of inflammatory bowel disease (IBD) including Chron’s Disease, Ulcerative Colitis, and IBS
• Treatment and prevention of other diseases mediated in part by the gut microbiome (e.g., diabetes, obesity, cancer)
• Consumer probiotic for maintenance of a healthy intestinal tract

Technology Advantages

• Colonization of LRCs may lead to long-term reduction of the pro-inflammatory response
• Co-administration of LRCs with IL-10 and IL-22 may enhance efficacy